基于高敏肌钙蛋白I的1小时快速急性冠脉综合征评估:美国阶梯楔形随机试验
RACE-IT试验为阶梯楔形随机试验,纳入美国9个急诊科2020年7月至2021年4月评估疑似心梗的32,609例患者,均接受高敏肌钙蛋白I检测且浓度≤99百分位。加速方案组(19,104例)采用0/1小时方案排除心梗后可离院,标准方案组(13,505例)采用0/3小时检测联合改良HEART评分决定离院。主要终点安全离院(离院且30天无死亡或心梗)在两组间无显著差异(59.5% vs 57.8%,aOR=1.05,95%CI 0.95-1.16);30天死亡或心梗分别38例(0.4%)和52例(0.4%)(aOR=0.84,95%CI 0.43-1.68)。结论:0/1小时加速方案未较标准方案增加安全离院。
要点
- 纳入32,609例疑似心梗且高敏肌钙蛋白I≤99百分位患者,0/1小时加速方案组19,104例,标准0/3小时方案组13,505例。
- 主要终点安全离院(离院且30天无死亡或心梗)两组无显著差异:标准组59.5% vs 加速组57.8%,aOR=1.05(95%CI 0.95-1.16)。
- 30天死亡或心梗:标准组38例(0.4%)vs 加速组52例(0.4%),aOR=0.84(95%CI 0.43-1.68)。
- 全队列58.7%(19,152例)直接从急诊离院。
- 加速方案可缩短评估时间,但本研究未显示其增加安全离院比例。
适用人群与场景
- 美国9个急诊科因疑似心梗接受评估的患者,共32,609例,纳入时间为2020年7月至2021年4月。
- 纳入标准:接受高敏肌钙蛋白I检测且浓度≤99百分位。
- 加速方案组:0/1小时方案排除心梗后可离院。
- 标准方案组:0小时和3小时肌钙蛋白检测,应用改良HEART评分合格后方可离院。
诊断标准与关键阈值
- 疑似心梗评估:高敏肌钙蛋白I浓度≤99百分位为纳入条件。
- 加速方案:采用0/1小时方案排除心梗后可离院。
- 标准方案:0小时和3小时肌钙蛋白检测,结合改良HEART评分决定离院资格。
处置流程与药物剂量
- 加速方案组:0小时和1小时检测高敏肌钙蛋白I,按方案排除心梗后可离院。
- 标准方案组:0小时和3小时检测肌钙蛋白,应用改良HEART评分合格后可离院。
- 研究未报告具体药物剂量。
研究设计与关键结果
- RACE-IT为阶梯楔形随机试验,覆盖9个急诊科,纳入32,609例疑似心梗患者。
- 加速方案组19,104例,标准方案组13,505例;全队列19,152例(58.7%)直接从急诊离院。
- 主要终点安全离院:标准组59.5% vs 加速组57.8%,aOR=1.05(95%CI 0.95-1.16),无显著差异。
- 30天死亡或心梗:标准组38例(0.4%)vs 加速组52例(0.4%),aOR=0.84(95%CI 0.43-1.68)。
证据类型、等级与局限
- 证据类型:阶梯楔形随机试验(RACE-IT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于疑似心梗且高敏肌钙蛋白I≤99百分位的急诊患者,0/1小时加速方案与0/3小时标准方案相比未增加安全离院比例(59.5% vs 57.8%,aOR=1.05,95%CI 0.95-1.16)。
- 加速方案组30天死亡或心梗发生率0.4%,标准方案组0.4%(aOR=0.84,95%CI 0.43-1.68)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: The real-world effectiveness and safety of a 0/1-hour accelerated protocol using high-sensitivity cardiac troponin (hs-cTn) to exclude myocardial infarction (MI) compared to routine care in the United States is uncertain. The objective was to compare a 0/1-hour accelerated protocol for evaluation of MI to a 0/3-hour standard care protocol.
METHODS: The RACE-IT trial was a stepped-wedge, randomized trial across 9 emergency departments (EDs) that enrolled 32,609 patients evaluated for possible MI from July 2020 through April 2021. Patients undergoing high-sensitivity cardiac troponin I testing with concentrations less than or equal to 99th percentile were included. Patients who had MI excluded by the 0/1-hour protocol could be discharged from the ED. Patients in the standard care protocol had 0- and 3-hour troponin testing and application of a modified HEART score to be eligible for discharge. The primary endpoint was the proportion of patients discharged from the ED without 30-day death or MI.
RESULTS: There were 13,505 and 19,104 patients evaluated in the standard care and accelerated protocol groups, respectively, of whom 19,152 (58.7%) were discharged directly from the ED. There was no significant difference in safe discharges between standard care and the accelerated protocol (59.5% vs 57.8%; adjusted odds ratio (aOR)=1.05, 95% confidence interval [CI] 0.95 to 1.16). At 30 days, there were 90 deaths or MIs with 38 (0.4%) in the standard care group and 52 (0.4%) in the accelerated protocol group (aOR=0.84, 95% CI 0.43 to 1.68).
CONCLUSION: A 0/1-hour accelerated protocol using high-sensitivity cardiac troponin I did not lead to more safe ED discharges compared with standard care.
参考来源
- Miller J, Cook B, Gandolfo C, et al. Rapid Acute Coronary Syndrome Evaluation Over One Hour With High-Sensitivity Cardiac Troponin I: A United States-Based Stepped-Wedge, Randomized Trial. Ann Emerg Med. 2024. PMID: 38888531. doi:10.1016/j.annemergmed.2024.04.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。